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oxygen consumption ACUTELY ADMINISTERED ENDOTHELIN (ET)-1 has positive inotropic effects in normal myocardium (22, 27) . In contrast, chronic ET-1 inhibition improves cardiac function and prognosis in animal models of heart failure (HF) (23, 29, 33) . Recently, Takeuchi et al. (35) reported that in addition to positive inotropic effects acutely administered exogenous ET-1 increases left ventricular (LV) chemomechanical energy conversion efficiency through ET type A (ET A ) receptor activation in normal rats. The role of endogenous ET-1 in energy utilization in HF, where chronic activation is present, has not been assessed in vitro. Moreover, there are no reports comparing ET A and ET B receptors in this setting.
To clarify these issues, we used the myocardial O 2 consumption (V O 2 )-pressure-volume area (PVA) framework to delineate effects of acute ET-1 blockade on mechanoenergetics in isolated, crystalloid-perfused hearts from Dahl salt-sensitive (DS) rats, which develop pressure and volume overload when fed a highsalt (HS) diet (4) . The V O 2 -PVA relationship allows quantification of energy conversion efficiency of the contractile machinery (contractile efficiency) and energy use for excitation-contraction (E-C) coupling and basal metabolism (6, 34) . We found that blockade of endogenous ET-1 in HF produces complex effects on V O 2 through ET A receptor inhibition. E-C coupling energy saving effects compensate for the energy-wasting effects on the contractile machinery, resulting in net reduction in energy consumption.
METHODS

Animal Model
All protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Vermont.
Sixty 6-wk-old male DS rats (Taconic Farms, Germantown, NY) were divided into groups receiving a HS (8% NaCl) or low-salt (LS) diet (0.3% NaCl). Compensated hypertrophy occurs after 5-6 wk of HS, with progression to HF after 9-12 wk (12, 15) . Transthoracic echocardiography was performed on the rats (1.5% isoflurane anesthesia) beginning at 15 wk of age (9 wk HS) with the use of a 15-MHz transducer (Sequoia C-256, Acuson). M-mode echocardiograms were recorded at the LV papillary muscle level to measure end-diastolic and end-systolic dimension, fractional shortening, and end-diastolic posterior wall thickness. HS rats without LV dilatation and decreased shortening after 9-12 wk of HS were excluded.
Each group was divided into subgroups receiving the dual ET A/ETB antagonist bosentan, the selective ETA antagonist BQ-123, the selective ET B antagonist BQ-788, or dimethylamyloride (DMA), a Na ϩ /H ϩ exchanger inhibitor, during isolated heart studies (see Isolated Heart Preparation). Thus there were eight subgroups, according to the presence or absence of HF and drug interventions: HF ϩ bosentan (n ϭ 8), BQ-123 (n ϭ 8), BQ-788 (n ϭ 8), or DMA (n ϭ 5) and age-matched controls ϩ bosentan (n ϭ 5), BQ-123 (n ϭ 5), BQ-788 (n ϭ 5), or DMA (n ϭ 3). In five additional HF hearts, BQ-123 and DMA were coadministered to determine whether the effects of coadministration differed quantitatively from each drug administered separately. to pH 7.4. Perfusion pressure was maintained constant at ϳ90 mmHg in controls and ϳ120 mmHg in HF rats. These pressures simulate in vivo conditions, and, based on our previous experience (15) , were expected to result in similar coronary flows per gram LV in control and failing hearts. A balloon containing a 2.5-French micromanometer was placed in the LV through the mitral orifice (15) . A pacing electrode was attached to the LV and used to pace at 240 beats/min (15) .
Mechanoenergetic Parameters
Coronary arteriovenous O 2 content difference (AVO2⌬) was measured with an Instech monitor (Instech Laboratories; Plymouth, PA). Perfusion pressure and AVO 2⌬ were stored for offline analyses. V O2/beat was calculated as coronary flow (ml/min) ϫ AVO2⌬ (vol%)/heart rate, and normalized per gram LV to yield total V O2 ⅐ beat Ϫ1 ⅐ g Ϫ1 (in ml). LV volume was determined as volume of water within the balloon plus its wall and connector volume. LV developed pressure (DP) was taken as peak minus minimum value and end-diastolic pressure (EDP) when rate of pressure development over time (ϩdP/dt) reached 10% of maximum. Rate of isovolumic pressure decay () was calculated using a nonzero asymptote (7) .
Experimental Protocol
The first series was designed to delineate the role of endogenous ET-1. The following were administered to HF and controls via the coronary perfusate: 1) bosentan (10 M); 2) BQ-123 (1 M); 3) BQ-788 (100 nM); 4) DMA (5 M); and 5) BQ-123 (1 M) ϩ DMA (5 M). Concentrations were determined from previously published studies (14, 24) . Hearts were allowed to stabilized for 20 min, following which LV pressure, coronary flow, and AVO 2⌬ were measured at various volumes (volume run) during steady-state contractions. Volume was varied between that where peak pressure was zero and a maximal volume (0.15 ml or diastolic pressure Ͼ20 mmHg). After a control run, one of the above agents was added to the perfusate for 20 min, and the volume run was repeated. To assess the effects on basal metabolism, three hearts in each group were arrested with intracoronary KCl at zero balloon volume after the first volume run. When coronary flow and AVO 2 stabilized, basal V O2 was measured for 1 min. Hearts were recovered by reinstituting normal perfusate and drug(s) then added to the perfusate. There were no significant differences in baseline hemodynamic measurements before and after recovery from KCl arrest. At the end of the study, KCl was readministered and basal V O2 measured after drug intervention. In a second series, dose-response relationships of ETA receptor blockade were examined with the use of a 10-fold greater (10 M, n ϭ 5) or a one-tenth lower (0.1 M, n ϭ 3) concentration of BQ-123.
Data Analysis
Systolic and diastolic function. For volume runs, EDP and peak-systolic pressure were plotted against LV volume (pressure-volume diagram). The end-systolic pressure-volume relation (ESPVR) was fitted to a nonlinear equation (2, 8, 15) 
where P and V are pressure and volume, V0 is the volume axis intercept, ␣ is a constant, and Emax is a contractility index. Contractility was also assessed as DP at a common volume (0.11 ml) in each heart. Diastolic function was quantified as EDP and at this same volume.
Mechanoenergetic parameters. Total mechanical energy output was quantified as PVA, the area circumscribed by the ESPVR, end-diastolic pressure-volume relation (EDPVR), and the systolic portion of the pressure-volume trajectory (34) . PVA was normalized per gram LV (in mmHg ⅐ ml ⅐ beat Ϫ1 ⅐ g Ϫ1 ). V O2 was plotted against PVA at the differing LV volumes and a linear regression (V O2 ϭ aPVA ϩ b) performed. Slope a ϭ O2 cost of PVA, and intercept b ϭ V O2 at 0 PVA (unloaded or PVA-independent V O2). PVA-independent V O2 consists of energy for E-C coupling and basal metabolism (34) . Slope a Ϫ1 ϭ conversion efficiency of V O2 to PVA (contractile efficiency) after conversion of PVA and V O2 to joules (2) . KCl arrest (basal metabolic) V O2 was expressed as ml O2 ⅐ min Ϫ1 ⅐ g Ϫ1 . E-C coupling V O2 (ml O2 ⅐ beat Ϫ1 ⅐ g Ϫ1 ) was estimated as PVA-independent V O2/min Ϫ V O2 for basal metabolism/min divided by heart rate. 
Statistical Analysis
Data are reported as means Ϯ SD. Differences between control and drug conditions were detected by Student's t-test. Differences in V O2-PVA regression lines between conditions were detected by analysis of covariance. Comparisons of variables among groups were made by one-way ANOVA. P Ͻ 0.05 was taken as significant. Table 1 summarizes echocardiographic and pathological parameters. HF rats had increased chamber diameter, decreased fractional shortening, and increased LV and lung-to-body weight ratio.
RESULTS
Baseline Echocardiographic, Postmortem, and Mechanoenergetic Parameters
As summarized in Tables 2 and 3 , under baseline conditions, E max was lower in HF than controls (average of all animals: 1,976 Ϯ 300 vs. 3,410 Ϯ 331 mmHg ⅐ g ⅐ ml Ϫ1 ; P Ͻ 0.05). DP was lower (66 Ϯ 5 vs. 105 Ϯ 10 mmHg; P Ͻ 0.05), and LVEDP (12.5 Ϯ 3.4 vs. 4.3 Ϯ 1.8 mmHg; P Ͻ 0.05), (31 Ϯ 0.5 vs. 21 Ϯ 0.6 ms; P Ͻ 0.05), and contractile efficiency (66 Ϯ 7 vs. 45 Ϯ 5%; P Ͻ 0.05) were higher in HF. Total V O 2 was ; P Ͻ 0.05).
ET-1 Blockade and Mechanics
As summarized in Table 2 , ET-1 blockade did not affect DP, EDP, , or E max in controls. Coronary blood flow was also unchanged. Table 3 summarizes the mechanoenergetics before and after drug interventions in HF. BQ-123 decreased DP (64 Ϯ 7 vs. 50 Ϯ 6 mmHg, P Ͻ 0.05), EDP (12.9 Ϯ 3.0 vs. 7.7 Ϯ 3.1 mmHg, P Ͻ 0.05), and (31 Ϯ 1.2 vs. 24 Ϯ 0.9 ms, P Ͻ 0.05). BQ-788 had no effect. Bosentan decreased DP, EDP, and similarly to BQ-123. BQ-123 modestly increased coronary blood flow (average 6.5%, P Ͻ 0.05), whereas bosentan and BQ-788 had no significant effect. Figure  1A shows effects of BQ-123 on pressure-volume relations in a representative failing heart. BQ-123 shifted ESPVR and EDPVR downward. Figure 1B shows group data for BQ-123, BQ-788, bosentan, and DMA in HF and controls. BQ-123 and bosentan decreased E max similarly (Ϫ16 Ϯ 3% and Ϫ18 Ϯ 2%, P Ͻ 0.05, Fig. 2A ). BQ-788 had no effect. Thus, in HF, ET A , and ET A /ET B 
Values are means Ϯ SD; n, no. of rats. V O2, myocardial O2 consumption; EDP, end-diastolic pressure; Emax, ESPVR slope; intercept, V O2-PVA intercept; BM, basal metabolism; E-C, excitation-contraction coupling V O2; efficiency, contractile efficiency. There were no significant differences among "before" conditions. 
ET-1 Blockade and Energetics
ET-1 blockade did not affect energy consumption in controls ( Table 2 ). Figure 2A shows V O 2 -PVA relations before and after BQ-123 in a representative failing heart. V O 2 was tightly correlated with PVA before and after BQ-123 (r Ͼ 0.95). In HF, BQ-123 increased the slope of the V O 2 -PVA relation and consequently decreased efficiency (average 17%, P Ͻ 0.05, Fig. 2B , Table 3 ). Similarly, bosentan decreased efficiency (Ϫ17 Ϯ 2%, P Ͻ 0.05), whereas BQ-788 had no effect (Fig. 2B) . BQ-123 shifted the V O 2 -intercept of the V O 2 -PVA relation downward (average 25%, P Ͻ 0.01, Fig.  2A , Table 3 ). Because basal metabolic V O 2 was unchanged after BQ-123, bosentan, or BQ-788, the decreased intercept after BQ-123 and bosentan was due to decreased E-C coupling V O 2 (Table 3) , amounting to 37 Ϯ 3% and 35 Ϯ 3%, respectively (Fig. 2C) . As shown in Table 3 and Fig. 2D , despite decreased efficiency total V O 2 decreased after BQ-123 and bosentan (Ϫ25 Ϯ 3% and Ϫ24 Ϯ 3%, respectively, P Ͻ 0.05). BQ-788 did not affect total V O 2 . Thus in HF ET A and ET A /ET B but not ET B blockade reduced total V O 2 by effects on E-C coupling despite decreased efficiency.
BQ-123 (10 M) decreased mechanoenergetic parameters to the same extent as 1 M BQ-123 (Table 3) . Treatment with 0.1 M BQ-123 had no significant effects (data not shown).
DMA and Mechanoenergetics
To explore the mechanism by which ET-1 blockade decreases contractility and V O 2 in HF, we examined the effects of Na ϩ /H ϩ exchange inhibition. DMA did not alter any of the mechanoenergetic parameters in controls ( Table 2 ). As shown in Table 3 and Figs. 1 and 2, in HF DMA decreased E max and PVA-independent, E-C coupling, and total V O 2 similarly to bosentan and BQ-123 but had no effect on efficiency, EDP, or .
Coadministration of BQ-123 and DMA to HF rats resulted in decreased E max (Ϫ15 Ϯ 3%, P Ͻ 0.05), E-C coupling V O 2 (Ϫ35 Ϯ 3%, P Ͻ 0.05), and total V O 2 (Ϫ22 Ϯ 2%, P Ͻ 0.05). The percent decrease in E max was similar to BQ-123 and DMA administered individually. Decreases in E-C coupling V O 2 and total V O 2 were virtually identical to BQ-123 alone and somewhat larger than those produced by DMA alone. Thus coadministration does not produce effects larger than those produced by the agent (BQ-123) with the greatest effects on E-C coupling V O 2 and total V O 2 . This suggests that BQ-123 and DMA do not have separate, additive effects on E max , E-C coupling, V O 2 or total V O 2 .
DISCUSSION
The present study in DS rats with heart failure demonstrates that 1) endogenous ET-1 has a positive inotropic effect, slows relaxation, and decreases enddiastolic distensibility; 2) despite decreasing contractile efficiency, ET A and ET A /ET B but not ET B blockade reduce total V O 2 by virtue of energy saving effects on E-C coupling; and 3) inhibition of Na ϩ /H ϩ exchange causes negative inotropic effects and decreases in V O 2 that are quantitatively similar to those induced by ET A and ET A /ET B blockade, without altering efficiency or relaxation.
Endogenous ET-1 and Function in Failing Heart
Our findings that acute ET-1 blockade results in a negative inotropic effect and improved relaxation via the ET A receptor in HF are consistent with Sakai et al. (30) , who reported similar effects of BQ-123 in the rat coronary ligation model. In contrast, data from other models suggest that ET-1 may have a blunted positive or even a negative inotropic effect (14, 32, 33, 36) . These inconsistencies may result from effects of antagonist-induced changes in loading conditions (decreased vascular resistance) on conventional measures of LV performance as well as variable anesthesia, species, HF severity, and experimental preparation.
Data from patients are also apparently discrepant. MacCarthy et al. (19) reported that BQ-123 had no effect on ϩdP/dt in patients with dilated cardiomyopathy but decreased ϩdP/dt in nonfailing controls. In Fig. 1 . A: left ventricular (LV) pressure-volume relations before (control) and after BQ-123 infusion in a representative failing heart. B: group changes in contractility index (Emax; as %change from baseline) for BQ-123, BQ-788, bosentan, and dimethylamyloride (DMA) in heart failure (HF) and controls. *P Ͻ 0.05 vs. controls. contrast, Serneri et al. (31) reported upregulation of ET-1 and a positive correlation of ET A receptor density with ejection fraction in patients with ischemic cardiomyopathy, suggesting that ET-1 maintains cardiac function. In agreement with the latter, ET-1 production and receptor density are increased in DS and coronary ligation rats (14, 17) . Thus, whereas there is substantial evidence that ET-1 upregulation supports cardiac function in HF, there is divergence with respect to acute effects of antagonists. Although we have specified potential reasons for these inconsistencies, we cannot reconcile them.
We did not specifically investigate the mechanism of enhanced relaxation by ET A and ET A /ET B blockade. These results are similar to those thought to be caused by ET B -mediated nitric oxide (NO) release with subsequent cGMP activation and decreased myofilament calcium responsiveness (37) . Because we observed that ET B blockade did not alter relaxation, some other mechanism must explain this effect of ET blockade. We (21) previously reported that Dahl rats with HF have increased half-maximal myofilament calcium sensitivity for tension production. Furthermore, we (25) recently documented decreased half-maximal calcium sensitivity of in vitro velocity of intact thin filaments isolated from Dahl rats with HF (25) . This thin filament defect was normalized by chronic bosentan treatment. Thus whereas a NO-mediated response is unlikely some other myofilament tension desensitizing effect may be responsible for enhanced relaxation produced by ET blockade, for example decreased intracellular pH due to reduced Na ϩ /H ϩ exchange (see below).
Endogenous ET-1 and PVA-independent V O 2 , Contractile Efficiency, and Total V O 2
Under basal conditions both PVA-independent V O 2 and E-C coupling V O 2 were reduced in HF rats. This is similar to our previous report (15) and is best explained by reduced basal Ca 2ϩ cycling in HF. This conclusion is supported by Yoneda et al. (38) , who reported reduced intracellular Ca 2ϩ transients in Dahl rats with heart failure. ET A and ET A /ET B but not ET B blockade shifted the V O 2 -PVA intercept downward in HF. This is attributable to decreased E-C coupling V O 2 and likely reflects additional depression of Ca 2ϩ cycling induced by ET A receptor inhibition (34) . Na ϩ /H ϩ exchanger inhibition decreased E max and E-C coupling V O 2 to a similar extent as ET A and ET A /ET B blockade, without altering efficiency or relaxation. Coadministration of BQ-123 and DMA resulted in changes in E max and E-C coupling V O 2 similar to those resulting from separate administration, suggesting a common mechanism for their effects on these parameters. ET-1 augments myofilament calcium responsiveness, at least in part through alkalinization caused by activation of Na ϩ /H ϩ exchange (18) . Activation of Na ϩ /H ϩ exchange would also be expected to increase activator Ca 2ϩ via secondary effects on Na ϩ /Ca 2ϩ exchange, which should increase E-C coupling V O 2 .
Because coronary perfusion pressure was higher in HF rats, a factor that could have influenced baseline levels of PVA-independent V O 2 in our studies is the Gregg effect or increased contractility occurring in conjunction with increased coronary perfusion pressure and/or flow. We (9) previously reported that the Gregg effect is associated with increases in PVA-independent V O 2 without changes in the slope of the V O 2 -PVA relation. Dijkman et al. (5) have shown that capillary pressure is in fact the main determinant of the Gregg effect. Therefore, to the extent that the higher perfu- sion pressure in HF rats resulted in higher capillary pressure this would have tended to improve contractility and increase PVA-independent V O 2 in HF rats, i.e., it would act as a bias against the results we found.
Recently, Takeuchi et al. (35) showed that exogenous ET-1 exerts a positive inotropic effect and increases efficiency through ET A activation. Positive inotropy is also due, at least in part, to increased Na (27) reported that ET-1 exerts inotropic effects through ET A receptor-mediated increased myofibrillar Ca 2ϩ responsiveness even in failing myocardium. They suggested that although the functional effects of ET-1 are attenuated, local ET is activated, implying impaired postreceptor signaling. Taken together, then, these observations suggest that inotropic effects and increased E-C coupling and total V O 2 produced by endogenous ET-1 in HF are mediated by a combination of increased activator Ca 2ϩ and increased myofilament Ca 2ϩ responsiveness resulting from activation of Na ϩ /H ϩ exchange. Contractile efficiency was markedly increased in HF and decreased after ET A and ET A /ET B antagonism. The former is consistent with our report of reduced myofibrillar ATPase activity in HF in association with increased efficiency (15) . In hyperthyroidism increased ATPase caused by increased ␣-myosin heavy chain isoform results in reduced efficiency (8) . Thus changes in ATPase cause directionally opposite changes in efficiency. McClellan et al. (20) reported that ET-1 decreases actomyosin ATPase activity in rat hearts and predicted that ET-1 increases efficiency, later confirmed by Takeuchi et al. (35) . ET-1 effects on crossbridge cycling are thought to be caused by protein kinase C-mediated phosphorylation of troponins I and T. It is also reported that myocardial ET-1 production is increased in failing DS rats (14) . Thus these studies and ours suggest that in HF ET-1 blockade reverses an increase in efficiency caused by endogenous ET-1-mediated alterations in troponin I and/or T phosphorylation. The lack of effect of DMA on efficiency in failing rats underscores the fact that ET-1 influences efficiency by a mechanism distinct from the Na ϩ /H ϩ exchange, i.e., its effect on myofibrillar ATPase activity.
Our most important finding is that ET-1 blockade caused a decrease in total V O 2 via ET A receptor inhibition as a result of E-C coupling energy saving effects being larger than contractile machinery energy wasting effects. To the extent that energy depletion occurs in HF (11) , increased efficiency caused by ET-1 may be cardioprotective. With respect to ET blockade, however, the net effect of decreased total V O 2 despite decreased efficiency should be favorable.
ET A versus ET B Receptors and Energy Consumption
ET B receptors mediate vasodilatation through NO and prostacyclin release from vascular endothelium (10) . Although our results demonstrate that ET B is not activated in failing DS rats, ET A blockade could result in secondary ET B receptor activation, with NO release. In isolated rat heart, Poderoso et al. (28) showed dosedependent decreases in total V O 2 with increasing NO concentration. In contrast, we reported that inhibition of NO synthase with L-NNA causes a small decrease in E-C coupling V O 2 , with no change in basal metabolic V O 2 or efficiency (24) . Thus increased NO in our preparation would be expected to slightly increase V O 2 . Therefore, a change in NO activity does not appear to play an important role in ET-1-mediated alterations in V O 2 in failing DS rats.
Clinical Implications
In conclusion, if energy depletion is important in HF, our results suggest that reduced V O 2 induced by ET A blockade should improve energy supply/demand and favorably affect outcomes via this mechanism.
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